Drug Profile
Letrozole extended release - Rovi Pharmaceuticals Laboratories
Alternative Names: Letrozole ISM®; Letrozole LEBELatest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Rovi
- Class Antineoplastics; Infertility therapies; Nitriles; Small molecules; Triazoles
- Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in Czech Republic (IM, Injection)
- 13 May 2021 Phase I development in Breast-cancer (In volunteers) is still ongoing in Czech Republic (IM,Injection)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in Czech Republic (IM, Injection)